Executive Director, Clinical Development
Mineralys Therapeutics
Executive Director, Clinical Development
Mineralys Therapeutics
Clinical-stage biopharma targeting aldosterone synthesis
“Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is headquartered in Radnor, Pennsylvania. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky”
Mineralys is a fully remote company.
Executive Director, Clinical Development
The Executive Director, Clinical Development will serve as the clinical lead for development program(s) and play a critical role in advancing pivotal studies, regulatory strategy, and submission readiness. This physician leader will provide medical and scientific oversight across the program lifecycle, from protocol design and study execution through data interpretation, regulatory interactions, and launch preparation.
This role requires a hands-on clinical development leader who thrives in a fast-paced biotech environment and can partner cross-functionally to drive high-quality execution with urgency.
Key Responsibilities:
Clinical Development Leadership
Medical Monitoring / Safety Oversight
Regulatory / Submission Support
Scientific / Cross-Functional Leadership
Team / Culture Leadership
Experience and Qualifications:
These positions are eligible for standard Company benefits including medical, dental, vision, time off and 401K, as well as participating in Mineralys incentive plans are contingent on achievement of personal and company performance. Actual compensation may vary from posted hiring range based on geographic location, work experience, education, and/or skill level.
US Salary Range: $340,000 - $370,000
#LI-REMOTE
Clinical-stage biopharma targeting aldosterone synthesis
Mineralys Therapeutics develops targeted treatments for diseases driven by dysregulated aldosterone, aiming to control blood pressure and prevent organ damage, led by lorundrostat. Lorundrostat is an oral aldosterone synthase inhibitor that blocks the CYP11B2 enzyme to lower aldosterone production, designed to reduce blood pressure with minimal cortisol disruption due to high selectivity. Compared with older non-selective MRAs, it lowers side effects by focusing on aldosterone synthesis rather than receptor blockade. The company's goal is to advance lorundrostat through late-stage trials toward regulatory approval and commercialization, while exploring expanded uses in CKD and OSA for a potential multi-hundred-billion market.
Explore more opportunities at Mineralys Therapeutics